Peter M. Loupos is the Founder and Managing Director of Princeton Healthcare Strategies, LLC, an advisor to the Biopharmaceutical network. He is inspired by the commitment and perseverance of the CMT community to address unmet needs through his work with Applied Therapeutics. His experience at the intersection of medical and pharmaceutical technology, AI/ML, research and development, data analytics, healthcare delivery, and policy and advocacy are the foundation for a holistic approach to identify breakthrough opportunities to accelerate medical innovation and improve patient outcomes. He is engaged with biotech and pharmaceutical companies on public affairs and advocacy initiatives, is a contributor to the Tufts Center for Biomedical System Design, and provides strategic guidance to AI healthcare startups. He is also a Board member of the Asthma and Allergy Foundation of America where he leads the Strategic Planning Committee and provides advisory support to patient advocacy organizations.
He began his career in HIT providing the vision, strategy, and leadership for the development of healthcare systems in the U.S., Europe, and Japan. He joined the pharmaceutical industry to lead the global R&D IT organization for the legacy companies of Sanofi and was recognized for his achievements in the design and delivery of industry unique solutions that facilitated changes to the R&D paradigm. Peter was a member of the R&D Strategic Initiatives group that addressed trends shaping healthcare. He was an early proponent of the integration of eHealth and R&D, led multi-stakeholder standards initiatives, and contributed to the launch of national and international R&D and HIT coalitions dedicated to improving healthcare for all. He led the PhRMA Information Management Policy group (IMPACC) during negotiations for the technology sections of the Pharmaceutical Drug Users Act IV and V commitment letters. As a member of the Corporate Affairs organization, Peter developed partnerships with the advocacy community to integrate patients and their perspectives throughout the R&D process and collaborated with advocates, providers, payers, and legislators on policies to reduce barriers to access and improve patient care.